Adverse effects of GLP-1 receptor agonists: difference between revisions
Diff·revision 6 → 7·07:12, 13 Aug 2024
Difference between revision 6 and revision 7 of Adverse effects of GLP-1 receptor agonists. 2 lines changed; the page grew by 263 bytes.
| Revision 6 — 10:11, 4 Aug 2024 EndotoxinEd (talk) fix a broken wikilink 2,320 bytes +275 | Revision 7 — 07:12, 13 Aug 2024 MergeMorwenna (talk) state that the frequency category follows the labelling convention 2,583 bytes +263 | ||
|---|---|---|---|
| 10 | Their mechanism is receptor-level rather than route-level: the same effects occur with an orally administered small-molecule agonist, which argues against a local gastrointestinal irritation explanation. Delayed [[Gastric emptying|gastric emptying]] and area postrema signalling are the proposed contributors.{{r|drucker2018}} | 10 | Their mechanism is receptor-level rather than route-level: the same effects occur with an orally administered small-molecule agonist, which argues against a local gastrointestinal irritation explanation. Delayed [[Gastric emptying|gastric emptying]] and area postrema signalling are the proposed contributors.{{r|drucker2018}} |
| 11 | 11 | ||
| + | 12 | Less common concerns include gallbladder disease, acute pancreatitis, and a labelled contraindication derived from rodent thyroid C-cell findings. Several of these are shared with rapid weight loss by other means, which complicates attribution.{{r|wilding2021}} | |
| + | 13 | ||
| 12 | == Gastrointestinal effects == | 14 | == Gastrointestinal effects == |
| 13 | | Effect | Approximate frequency at higher doses | Course | | 15 | | Effect | Approximate frequency at higher doses | Course | |